NMMI diagnostic with 5X greater efficacy to become "gold standard in the $156B INV industry. "

Our global JV will include Clinexel Life Sciences, the MHI CRO unit, as well as Linical Amercias to implement our PH III clinical trials. Regulatory approval will be fast-tracked due to our focus on crisis-type diseases.
Support and sponsorship of those activities will involve government agencies and related NGOs that focus on those specific diseases and have a committed patient treatment timeline of 2030 for detection and monitoring to mitigate population and further impact toward country risk.
When combined, our India and African involvement will generate $300m+ net margin income over that period of time.
Our therapeutics and device adaptations will be US-based to enter into multi-continent pharma licensing agreements on an international basis.

Successful Phase I & II clinical trials proved its efficacy to be 5x greater than the US standard diagnostic treatment. The Nuclear medicine and molecular imaging (NMMI) technology was designed to focus on pulmonary diseases. Our product development growth plan will expand its worldwide patient care to include a TB derivative, lung-cancer, sickle-cell, and others planned for commercialization and distribution.

To date, the business has been self-funded. Our global initiative will be financed through an offering by Marquee Equity in India, in addition to a digital asset capital raise through INX, which operates in 73 countries and is regulatory approved and SEC-compliant. At this time through Dec, 31, '23, we are offering a $3m investor participaition, for early-stage investors. In January '24, Marquee will increase the offering to $30m, to be compliment by the INX digital asset raise for up to $50m. For institutional type investor relationships, an opportunity is available to be a stakeholder in the holding company.

Our valuation was recently updated by Marquee Equity to reflect $223m, due to the projected monthly and yearly patient treatments administered by the various governments and NGO sponsors. Based on an independent market analysis by DyoDelta Biosciences in London, our primary pulmonary disease focus is projected to average $78m/yr. , over a five year period, from pharma licensing agreement contracts.